文献速递烧伤创面修复

ReCell®装置与自体刃厚网状皮片移植治疗急性烧伤的对比研究

A Comparative Study of the ReCell® Device and Autologous Spit-Thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries.
PubMed 文献 · J Burn Care Res · 2018-01-01

一项前瞻性研究比较ReCell®自体细胞收获装置制备的非培养自体皮肤细胞悬液(ASCS)与网状刃厚皮片移植(STSG,对照)治疗深二度烧伤的效果,随访至1年。4周时ASCS治疗部位愈合率98% vs 对照100%,瘢痕与疼痛相似;ReCell供区面积约为对照的1/40(P<.0001),1周时供区愈合比例更高(P=.04),前16周供区疼痛显著更低(各时间点P≤.05),患者对ReCell供区结局满意度更高。

要点

  • 4周时ASCS治疗部位愈合率98%,对照部位为100%。
  • ReCell供区平均面积约为对照供区的1/40(P<.0001)。
  • 前16周ReCell供区疼痛较对照显著更低(各时间点P≤.05)。

核心结论

  • ASCS治疗深二度烧伤可获得与STSG相当的愈合,且供区面积和疼痛显著减少、外观改善。

研究设计与样本

  • 前瞻性研究,比较ReCell制备的ASCS与网状刃厚皮片移植(STSG,对照)治疗深二度烧伤,随访至1年。

主要发现

  • 4周时ASCS治疗部位愈合率98%,对照部位为100%。
  • 治疗部位疼痛与瘢痕评估两组相似。
  • ReCell供区平均面积约为对照供区的1/40(P<.0001)。
  • 1周后ReCell供区愈合比例显著高于对照(P=.04)。
  • 前16周患者报告ReCell供区疼痛较对照显著更低(各时间点P≤.05),长期随访对ReCell供区结局满意度更高。

关键数值与推荐

  • 4周愈合率:ASCS治疗部位98% vs 对照部位100%。
  • ReCell供区平均面积约为对照供区的1/40(P<.0001)。
  • 1周供区愈合:ReCell供区显著多于对照供区(P=.04)。
  • 前16周供区疼痛:ReCell供区显著低于对照供区(各时间点P≤.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Early excision and autografting are standard care for deeper burns. However, donor sites are a source of significant morbidity. To address this, the ReCell® Autologous Cell Harvesting Device (ReCell) was designed for use at the point-of-care to prepare a noncultured, autologous skin cell suspension (ASCS) capable of epidermal regeneration using minimal donor skin. A prospective study was conducted to evaluate the clinical performance of ReCell vs meshed split-thickness skin grafts (STSG, Control) for the treatment of deep partial-thickness burns. Effectiveness measures were assessed to 1 year for both ASCS and Control treatment sites and donor sites, including the incidence of healing, scarring, and pain. At 4 weeks, 98% of the ASCS-treated sites were healed compared with 100% of the Controls. Pain and assessments of scarring at the treatment sites were reported to be similar between groups. Significant differences were observed between ReCell and Control donor sites. The mean ReCell donor area was approximately 40 times smaller than that of the Control (P < .0001), and after 1 week, significantly more ReCell donor sites were healed than Controls (P = .04). Over the first 16 weeks, patients reported significantly less pain at the ReCell donor sites compared with Controls (P ≤ .05 at each time point). Long-term patients reported higher satisfaction with ReCell donor site outcomes compared with the Controls. This study provides evidence that the treatment of deep partial-thickness burns with ASCS results in comparable healing, with significantly reduced donor site size and pain and improved appearance relative to STSG.

来源:J Burn Care Res,查看原文。版权归原作者所有。

引用

  1. Holmes Iv JH, Molnar JA, Carter JE, et al. A Comparative Study of the ReCell® Device and Autologous Spit-Thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries. J Burn Care Res. 2018. PMID: 29800234. doi:10.1093/jbcr/iry029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。